Revenues derived from the Bioprocessing Systems Operations which comprise primarily of net royalties accrued from sublicensees increased by $76,500 (145.2%) to $129,200 for the three months ended September 30, 2018 compared to $52,700 for the three months ended September 30, 2017.
  Overview.
Goodwill amounted to $705,300 at September 30, 2018 and June 30, 2018, all of which is expected to be deductible for tax purposes.
 The Company reflected income tax expense of $35,500 for the three months ended September 30, 2018 compared to a tax benefit of $73,900 for the three months ended September 30, 2017, primarily due to the income generated during the three months ended September 30, 2018.
 The gross profit percentage for the three months ended September 30, 2018 was 46.4% compared to 35.3% for the three months ended September 30, 2017.
Sales of catalyst research instruments increased by $188,800 to $217,500 for the three months ended September 30, 2018 compared to $28,700 for the three months ended September 30, 2017 because there were no large orders shipped during the prior year period.
The Company reflected income before tax expense of $177,500 for the three months ended September 30, 2018 compared to a loss before income tax benefit of $306,500 for the three months ended September 30, 2017, primarily the result of increased revenues across all business segments.
The results reflected total non-cash amounts for depreciation and amortization of $75,900 and $77,100 for the three months ended September 30, 2018 and 2017, respectively.
Consequently, no forward-looking statement can be guaranteed.
 As a result of the foregoing, the Company recorded net income of $142,000 for the three months ended September 30, 2018 compared to a net loss of $232,600 for the three months ended September 30, 2017.
  Forward-Looking statements.
The benchtop laboratory equipment sales reflected $425,300 of Torbal brand product sales for the three months ended September 30, 2018, compared to $304,200 in the three months ended September 30, 2017 as a result of continued growth in sales of the new force gauges product line.
 Selling expenses for the three months ended September 30, 2018 increased $35,100 (17.5%) to $236,100 from $201,000 for the three months ended September 30, 2017 primarily due to increased sales and marketing activities by the Benchtop Laboratory Equipment Operations.
As of September 30, 2018, the order backlog for catalyst research instruments was $329,400, all of which is expected to be shipped during the fiscal year ending June 30, 2019, compared to $323,900 as of September 30, 2017.
As of September 30, 2018, estimated future amortization expense related to intangible assets is $125,900 for the remainder of the fiscal year ending June 30, 2019, $66,400 for fiscal 2020, $49,100 for fiscal 2021, $26,100 for fiscal 2022, $9,800 for fiscal 2023, and $1,600 thereafter.